Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Matthew Langer Meyerson, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Matthew Meyerson and William Sellers.
Connection Strength

1.983
  1. EGFR gene mutations: a call for global x global views of cancer. J Natl Cancer Inst. 2005 Mar 02; 97(5):326-8.
    View in: PubMed
    Score: 0.315
  2. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905.
    View in: PubMed
    Score: 0.111
  3. Major copy proportion analysis of tumor samples using SNP arrays. BMC Bioinformatics. 2008 Apr 21; 9:204.
    View in: PubMed
    Score: 0.098
  4. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):20007-12.
    View in: PubMed
    Score: 0.095
  5. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med. 2006 Jul; 12(7):852-5.
    View in: PubMed
    Score: 0.086
  6. Allele-specific amplification in cancer revealed by SNP array analysis. PLoS Comput Biol. 2005 Nov; 1(6):e65.
    View in: PubMed
    Score: 0.083
  7. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov; 2(11):e313.
    View in: PubMed
    Score: 0.082
  8. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005 Jul 07; 436(7047):117-22.
    View in: PubMed
    Score: 0.081
  9. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 2005 Jul 01; 65(13):5561-70.
    View in: PubMed
    Score: 0.081
  10. "Lineage addiction" in human cancer: lessons from integrated genomics. Cold Spring Harb Symp Quant Biol. 2005; 70:25-34.
    View in: PubMed
    Score: 0.078
  11. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. Cold Spring Harb Symp Quant Biol. 2005; 70:73-81.
    View in: PubMed
    Score: 0.078
  12. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood. 2004 Sep 15; 104(6):1855-8.
    View in: PubMed
    Score: 0.075
  13. Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res. 2004 May 18; 32(9):e71.
    View in: PubMed
    Score: 0.075
  14. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res. 2004 May 01; 64(9):3060-71.
    View in: PubMed
    Score: 0.074
  15. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 04; 304(5676):1497-500.
    View in: PubMed
    Score: 0.074
  16. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res. 2003 Aug 15; 63(16):4781-5.
    View in: PubMed
    Score: 0.071
  17. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2019 01; 565(7738):E5-E6.
    View in: PubMed
    Score: 0.051
  18. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012 Mar 28; 483(7391):603-7.
    View in: PubMed
    Score: 0.032
  19. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010 Aug; 42(8):715-21.
    View in: PubMed
    Score: 0.029
  20. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009 Jun 01; 69(11):4674-81.
    View in: PubMed
    Score: 0.026
  21. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 2008 Aug 15; 68(16):6779-88.
    View in: PubMed
    Score: 0.025
  22. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008 Jun 24; 105(25):8713-7.
    View in: PubMed
    Score: 0.025
  23. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol. 2008 Feb; 32(2):307-16.
    View in: PubMed
    Score: 0.024
  24. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008 Feb 01; 68(3):664-73.
    View in: PubMed
    Score: 0.024
  25. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51.
    View in: PubMed
    Score: 0.023
  26. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec; 3(12):e485.
    View in: PubMed
    Score: 0.022
  27. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006 Sep 01; 66(17):8337-41.
    View in: PubMed
    Score: 0.022
  28. Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol. 2006 May; 2(5):e41.
    View in: PubMed
    Score: 0.021
  29. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res. 2006 Mar 15; 66(6):3162-8.
    View in: PubMed
    Score: 0.021
  30. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 2005 Oct 01; 65(19):8968-74.
    View in: PubMed
    Score: 0.021
  31. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr; 7(4):387-97.
    View in: PubMed
    Score: 0.020
  32. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004 Dec 15; 64(24):8816-20.
    View in: PubMed
    Score: 0.019
  33. Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res. 2004 Sep; 2(9):489-94.
    View in: PubMed
    Score: 0.019
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.